Dr. Agarwal’s Health Care: Q1 FY27 Revenue Grows 26% to ₹614 Crore

Dr. Agarwal’s Health Care Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026 (Q1 FY2027). The company reported a 26.0% year-on-year growth in revenue from operations, reaching ₹614 crore. Total income increased by 23.9% to ₹620 crore. EBITDA saw a rise of 25.2% to ₹177 crore, while Profit After Tax (PAT) grew by a substantial 44.6% to ₹55 crore.

Strong Q1 Performance

Dr. Agarwal’s Health Care Limited has announced robust financial results for the first quarter of the financial year 2027 (Q1 FY2027), ending June 30, 2026. The company experienced significant year-on-year growth across key financial metrics, underscoring a strong operational performance.

Key Financial Highlights (Q1 FY2027 vs. Q1 FY2026)

  • Revenue from Operations: Increased by 26.0% to ₹614 crore.
  • Total Income: Grew by 23.9% to ₹620 crore.
  • IND-AS EBITDA: Rose by 25.2% to ₹177 crore, with EBITDA margins at 28.5%.
  • Profit After Tax (PAT): Saw a notable increase of 44.6% to ₹55 crore, with PAT margins at 8.9%.

Operational Achievements

The company also highlighted operational milestones achieved during the quarter. As of June 30, 2026, Dr. Agarwal’s network expanded to 304 facilities, with 18 new facilities added during the quarter. This includes 1 Tertiary, 15 Secondary, and 2 Primary facilities. Furthermore, 16 new surgical facilities were commissioned, marking a quarterly record for the company. The company performed 91,082 surgeries, a 15.5% YoY growth.

Auditor Appointments and Subsidiary Incorporation

The Board of Directors also approved the appointment of M/s. S.R. Batliboi & Associates LLP as the Statutory Auditors until the conclusion of the 20th Annual General Meeting (AGM). Additionally, M/s. KPMG Assurance and Consulting Services LLP were appointed as Internal Auditors for the financial year 2026-27, and M/s. B Y & Associates were re-appointed as Cost Auditors for the same period. The company also proposed the incorporation of a wholly owned subsidiary in Nigeria via its existing subsidiary in Mauritius.

Source: BSE

Previous Article

BASF India: Approves Closure of Dahej Care Chemicals Plants

Next Article

Pidilite Industries: Q1 FY27 Unaudited Results Show Strong Performance